Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | PDE5A | O76074 | 10/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | GUCY1A1 | Q02108 | 3/20 | 0.44 |
| ▸ | GUCY1B1 | Q02153 | 3/20 | 0.44 |
| ▸ | CFD | P00746 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937101 | 1.00 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL6068600 | 0.91 | CFD (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL174160 | 0.89 | ATM (0.54) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL2878097 | 0.88 | ADORA3 (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL255820 | 0.88 | ADORA3 (0.50) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL175370 | 0.88 | ATM (0.53) | ATMADORA3KCNH2PDE5AMAPT | |
| Hydrochloric Acid SCHEMBL174837 | 0.87 | ADORA3 (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| Hydrochloric Acid SCHEMBL30507586 | 0.87 | ADORA3 (0.49) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL2883924 | 0.86 | ADORA3 (0.46) | ATMADORA3KCNH2PDE5AMAPT | |
| SCHEMBL8220418 | 0.86 | ADORA3 (0.46) | ATMADORA3KCNH2PDE5AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7317016-B2 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20070225299-A1 | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance | BAYER HEALTHCARE AG (DE) | 2007-09-27 | — | — | US | disclosed |
| US-7135474-B2 | Derivatives of 2-(1-benzyl-1H-pyrazolo(3,4-B)pyridine-3-yl)-5(-4-pyridinyl)l-4-pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER HEALTHCARE AG (DE) | 2006-11-14 | — | — | US | disclosed |
| US-7115599-B2 | Sulfonamide-substituted pyrazolopyridine compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-03 | — | — | US | disclosed |
| US-7105523-B2 | Carbamate-substituted pyrazolopyridine-derivatives | BAYER AKTIENGESELISCHAFT (DE) | 2006-09-12 | — | — | US | disclosed |
| US-20050245553-A1 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-11-03 | — | — | US | disclosed |
| EP-1102767-B1 | SUBSTITUTED PYRAZOLE DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2005-11-02 | — | — | EP | disclosed |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2005-10-06 | — | — | US | disclosed |
| US-6919345-B2 | Sulfonate substituted pyrazol pyridine derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 2005-07-19 | — | — | US | disclosed |
| US-6833364-B1 | Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine | BAYER HEALTHCARE AG (DE) | 2004-12-21 | — | — | US | disclosed |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20040224945-A1 | Novel substituted pyrazole derivatives | BAYER HEALTHCARE AG (DE) | 2004-11-11 | — | — | US | disclosed |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-02 | — | — | US | disclosed |
| US-6743798-B1 | CARDIOVASCULAR DISORDERS; VASORELAXATION, INHIBITION OF PLATELET AGGREGATION, DECREASE IN BLOOD PRESSURE; STIMULATION OF SOLUBLE GUANYLATE CYCLASE AND AN INTRACELLULAR CGMP INCREASE | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-01 | — | — | US | disclosed |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-29 | — | — | US | disclosed |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-04-08 | — | — | US | disclosed |
| US-6693102-B2 | CARDIOVASCULAR DISORDERS; HYPOTENSIVE AGENTS; CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-02-17 | — | — | US | disclosed |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | BAYER HEALTHCARE AG (DE) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040224945-A1 | Novel substituted pyrazole derivatives | CYP11B2, CYP11B1, ADRB3 | ATM 3044/4885ADORA3 260/4885KCNH2 1026/4885 |
| US-20050245553-A1 | Methods of treating medical conditions using sulfonate-substituted pyrazolopyridine derivatives | PTGER3, TBXA2R, STS | ATM 1076/4885ADORA3 444/4885KCNH2 346/4885 |
| US-20070225299-A1 | Novel Combination Containing a Stimulator of Soluble Guanylate Cyclase and a Lipid-Lowering Substance | GUCY1A2, GUCY1B2, GUCY1B1 | ATM 3510/4885ADORA3 928/4885KCNH2 2335/4885 |
| US-20050222170-A1 | Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)- 5(-4-pyridiny)l-4- pyrimidinamines and the use thereof as quanylate cyclase stimulators | PDE3B, PDE5A, PDE3A | ATM 2115/4885ADORA3 301/4885KCNH2 295/4885 |
| US-20020173514-A1 | Pyridine-substituted pyrazolopyridine derivatives | GUCY1A1, GUCY1A2, GUCY1B1 | ATM 2036/4885ADORA3 448/4885KCNH2 155/4885 |
| US-20040082596-A1 | Novel carbamate-substituted pyrazolopyridine derivatives | GPR3, NOS3, NPR3 | ATM 1041/4885ADORA3 160/4885KCNH2 200/4885 |
| US-20040171832-A1 | Novel sulfonate substituted pyrazol pyridine derivatives | NOS3, PDE3A, GPR3 | ATM 379/4885ADORA3 112/4885KCNH2 605/4885 |
| US-20040067937-A1 | Novel sulfonamide-substituted pyrazolopyridine derivatives | GUCY1A2, GUCY1A1, GUCY1B2 | ATM 688/4885ADORA3 318/4885KCNH2 325/4885 |
| US-20040235863-A1 | Morpholine-bridged pyrazolopyridine derivatives | GUCY1A1, PDE1A, PDE3B | ATM 1075/4885ADORA3 803/4885KCNH2 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.